Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by George Washington University.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
George Washington University
ClinicalTrials.gov Identifier:
NCT01206933
First received: September 17, 2010
Last updated: January 3, 2014
Last verified: September 2010
History of Changes
  Purpose

Investigators in the Division of Infectious Diseases and the Departments of Biochemistry and Molecular Biology of The George Washington University Medical Center are carrying out a research study to determine why patients with Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) co-infection (HIV/HCV) have a more rapid and progressive course of HCV infection, leading to fatty infiltration of the liver and cirrhosis.


Condition
Human Immunodeficiency Virus (HIV)
Hepatitis C, Chronic

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by George Washington University:

Primary Outcome Measures:
  • Laboratory analysis of Tat Protein [ Time Frame: Single sample analysis ] [ Designated as safety issue: No ]
    The validation that HIV Tat protein is a potent inducer of HCV in dual infected patients will likely lead to anti-tat therapy to manage HCV patients for whom treatment options are rather limited.
Estimated Enrollment: 30
Study Start Date: July 2010
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
Detectable HIV RNA and HCV RNA
Undetectable HIV and Detectable HCV
HIV and HCV infected, HIV RNA Undetectable(treated) and Detectable HCV RNA.
Undetectable HIV and HCV
HIV and HCV infected, Undetectable HIV RNA and HCV RNA
Undetectable HCV
HCV(mono-infected,) HCV RNA undetectable
Detectable HCV RNA
Monoinfected HCV, detectable RNA
Detectable HIV RNA
Monoinfected HIV, Detectable RNA

Detailed Description:

Samples will be collected from 4 groups of patients with HIV/HCV infection, identified by the virologic control of either HIV, HCV, or both. Sera will be used in an in-vitro hepatocyte model of hepatitis C infection to better understand the pathogenesis of HIV/HCV co-infection, and to gain insight into intracellular mechanisms.

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Four groups of subjects will be included in this study, with 5 participants in each group:

  1. detectable HIV RNA (Ribonucleic Acid) and detectable HCV RNA
  2. undetectable HIV RNA (treated) and detectable HCV RNA
  3. undetectable HIV RNA (treated) and undetectable HCV RNA
  4. undetectable HCV RNA (mono-infected)
  5. detectable HCV RNA (mono-infected)
  6. detectable HIV RNA (mono-infected)
Criteria

Inclusion Criteria:

  • Meets one of the following criteria:

    1. detectable HIV RNA and detectable HCV RNA
    2. undetectable HIV RNA (treated) and detectable HCV RNA
    3. undetectable HIV RNA (treated) and undetectable HCV RNA
    4. undetectable HCV RNA (mono-infected)
    5. detectable HCV RNA (mono-infected)
    6. detectable HIV RNA (mono-infected)

Participants will be men and women, ages 18 and older, and who are patients being seen in the clinics of the Medical Faculty Associates, and meet the above criteria.

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01206933

Contacts
Contact: Nicole Bisby 202-741-2230

Locations
United States, District of Columbia
George Washington University Medical Faculty Associates Recruiting
Washington, District of Columbia, United States, 20037
Contact: Nicole Bisby    202-741-2230      
Principal Investigator: David Parenti, MD         
Sponsors and Collaborators
George Washington University
Investigators
Principal Investigator: David Parenti, MD George Washington University
  More Information

No publications provided

Responsible Party: George Washington University
ClinicalTrials.gov Identifier: NCT01206933     History of Changes
Other Study ID Numbers: GWUIRB #061012
Study First Received: September 17, 2010
Last Updated: January 3, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by George Washington University:
HIV/HCV Coinfection
Tat Protein
HCV

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Hepatitis C, Chronic
Digestive System Diseases
Flaviviridae Infections
Hepatitis
Hepatitis C
Hepatitis, Chronic
Hepatitis, Viral, Human
Immune System Diseases
 Immunologic Deficiency Syndromes
Lentivirus Infections
Liver Diseases
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases

ClinicalTrials.gov processed this record on March 03, 2015